Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis

LIN Lili; YAO Nannan; WU Jue; LIU Zhihong; SONG Hongtao

doi:10.3969/j.issn.1006-0111.2019.05.018

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 37 Issue 5

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2019 > 37(5): 473-480

LIN Lili, YAO Nannan, WU Jue, LIU Zhihong, SONG Hongtao. Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018

Citation:

LIN Lili, YAO Nannan, WU Jue, LIU Zhihong, SONG Hongtao. Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018

Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis

doi: 10.3969/j.issn.1006-0111.2019.05.018

1.
Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
2.
Department of Pharmacy, No. 900 Hospital of Joint Service Support Force, Fuzhou 350025, China

Received Date: 2018-10-10
Rev Recd Date: 2018-12-29

Abstract

Objective To evaluate the efficacy and safety of once-daily fluticasone furoate/vilanterol compared with ICS alone or twice-daily ICS/LABA formulations in patients with asthma. Methods Systematic search was performed for randomized controlled trials in the CNKI,PubMed,Embase and Cochrane Library. Results 10 citations contained 9 811 patients with asthma met the selection criteria. In terms of efficacy,compared with the control group,the patient's trough forced expiratory volume in one second[WMD=0.09,95% Cl(0.05,0.13) P=0.000] and asthma control Test score[WMD=0.63,95% CI(0.24,1.03),P=0.002] were increased in the FF/VI group. In terms of safety,the risk of adverse reaction events associated with treatment in patients was not increased in the FF/VI group compared to the control group[RR=1.15,95% CI(0.98,1.36),P=0.000]. Conclusion FF/VI had advantages and better tolerance in treating asthma patients. It is recommended to be used for its once-daily use of the frequency,which was the advantage of improving patient adherence.
- fluticasone furoate,
- vilanterol,
- ICS,
- LABA,
- asthma,
- Meta-analysis

References

[1]	林燕萍.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案)[C].中国中西医结合变态反应学术会议.2009.
[2]	BATEMAN E D,HURD S S,BARNES P J,et al. Global strategy for asthma management and prevention:GINA executive summary[J].Eur Respir J,2008,31(1):143-178.
[3]	BLAIS L,SUISSA S,BOIVIN J F,et al. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma[J].Thorax,1998,53(12):1025-1029.
[4]	SHIMODA T,OBASE Y,KISHIKAWA R,et al. Impact of inhaled corticosteroid treatment on 15-year longitudinal respiratory function changes in adult patients with bronchial asthma[J].Int Arch Allergy Immunol,2013,162(4):323-329.
[5]	SUISSA S,ERNST P,BENAYOUN S,et al. Low-dose inhaled corticosteroids and the prevention of death from asthma[J].N Engl J Med,2000,343(5):332-336.
[6]	TOY E L,BEAULIEU N U,MCHALE J M,et al. Treatment of COPD:Relationships between daily dosing frequency,adherence,resource use,and costs[J].Respir Med,2011,105(3):435-441.
[7]	GAMBLE J,STEVENSON M,MCCLEAN E,et al. The prevalence of nonadherence in difficult asthma[J]. Am J Respir Crit Care Med,2009,180(9):817-822.
[8]	BERNSTEIN D I,BATEMAN E D,WOODCOCK A,et al. Fluticasone furoate (FF)/vilanterol (100/25mcg or 200/25mcg) or FF (100mcg) in persistent asthma[J]. J Asthma,2015,52(10):1073-1083.
[9]	DEVILLIER P,HUMBERT M,BOYE A,et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β₂-agonists (ICS/LABA) in patients with uncontrolled asthma:An open-label,randomized,controlled trial[J].Respir Med,2018,141:111-120.
[10]	JACQUES L,BAKERLY N D,NEW J P,et al. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study[J].J Asthma,2018:1-10.
[11]	张菲,江兵,缪李丽.糠酸氟替卡松治疗支气管哮喘疗效及安全性的系统评价[J].中国循证医学杂志,2017,17(1):33-39.
[12]	MOHER D,LIBERATI A,TETZLAFF J,et al. Preferred reporting items for systematic reviews and meta-analyses:The PRISMA statement[J].Int J Surg,2010,8(5):336-341.
[13]	BUSSE W W,O'BYRNE P M,BLEECKER E R,et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β₂-agonist vilanterol administered once daily for 52 weeks in patients ≥ 12 years old with asthma:a randomised trial[J].Thorax,2013,68(6):513-520.
[14]	WOODCOCK A,BLEECKER E R,LOTVALL J,et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma:a randomized trial[J].Chest,2013,144(4):1222-1229.
[15]	O'BYRNE P M,BLEECKER E R,BATEMAN E D,et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma[J].Eur Respir J,2014,43(3):773-782.
[16]	BATEMAN E D,O'BYRNE P M,BUSSE W W,et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone[J].Thorax,2014,69(4):312-319.
[17]	BLEECKER E R,LOTVALL J,O'BYRNE P M,et al. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma:a randomized trial[J].J Allergy Clin Immunol Pract,2014,2(5):553-561.
[18]	LIN J,KANG J,LEE S H,et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients:A randomized trial[J].Respir Med,2015,109(1):44-53.
[19]	BERNSTEIN D I,BATEMAN E D,WOODCOCK A,et al. Fluticasone furoate (FF)/vilanterol (100/25mcg or 200/25mcg) or FF (100mcg) in persistent asthma[J]. J Asthma,2015,52(10):1073-1083.
[20]	GROSS A S,GOLDFRAD C,HOZAWA S,et al. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase Ⅱb/Ⅲ trials[J]. Bmc Pulm Med,2015,15(1).
[21]	DEVILLIER P,HUMBERT M,BOYE A,et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β₂-agonists (ICS/LABA) in patients with uncontrolled asthma:An open-label,randomized,controlled trial[J].Respir Med,2018,141:111-120.
[22]	BIGGADIKE K. Fluticasone furoate/fluticasone propionate-different drugs with different properties[J].Clin Respir J,2011,5(3):183-184.
[23]	BIGGADIKE K,BLEDSOE R K,HASSELL A M,et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocoricoid receptor ligand binding domain[J].J Med Chem,2008,51(12):3349-3352.
[24]	SALTER M,BIGGADIKE K,MATTHEWS J L,et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease[J].Am J Physiol-Lung C,2007,293(3):L660-L667.
[25]	VALOTIS A,HOGGER P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate[J].Respir Res,2007,8:54.
[26]	ALLEN A,BAREILLE P J,ROUSELL V M. Fluticasone furoate,a novel inhaled corticosteroid,demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate[J].Clin Pharmacokinet,2013,52(1):37-42.
[27]	ROSSIOS C,TO Y,TO M,et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells[J].Eur J Pharmacol,2011,670(1):244-251.
[28]	PROCOPIOU P A,BARRETT V J,BEVAN N J,et al. Synthesis and structure activity relationships of long-acting β₂ adrenergic receptor agonists incorporating metabolic inactivation:an antedrug approach[J].J Med Chem,2010,53(11):4522-4530.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(3520) PDF downloads(328) Cited by()

Proportional views

Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis

1. Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China

2. Department of Pharmacy, No. 900 Hospital of Joint Service Support Force, Fuzhou 350025, China

Received Date: 2018-10-10

Rev Recd Date: 2018-12-29

Key words:

Abstract: Objective To evaluate the efficacy and safety of once-daily fluticasone furoate/vilanterol compared with ICS alone or twice-daily ICS/LABA formulations in patients with asthma. Methods Systematic search was performed for randomized controlled trials in the CNKI,PubMed,Embase and Cochrane Library. Results 10 citations contained 9 811 patients with asthma met the selection criteria. In terms of efficacy,compared with the control group,the patient's trough forced expiratory volume in one second[WMD=0.09,95% Cl(0.05,0.13) P=0.000] and asthma control Test score[WMD=0.63,95% CI(0.24,1.03),P=0.002] were increased in the FF/VI group. In terms of safety,the risk of adverse reaction events associated with treatment in patients was not increased in the FF/VI group compared to the control group[RR=1.15,95% CI(0.98,1.36),P=0.000]. Conclusion FF/VI had advantages and better tolerance in treating asthma patients. It is recommended to be used for its once-daily use of the frequency,which was the advantage of improving patient adherence.

HTML

Reference (28)

[1]	林燕萍.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案)[C].中国中西医结合变态反应学术会议.2009.
[2]	BATEMAN E D,HURD S S,BARNES P J,et al. Global strategy for asthma management and prevention:GINA executive summary[J].Eur Respir J,2008,31(1):143-178.
[3]	BLAIS L,SUISSA S,BOIVIN J F,et al. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma[J].Thorax,1998,53(12):1025-1029.
[4]	SHIMODA T,OBASE Y,KISHIKAWA R,et al. Impact of inhaled corticosteroid treatment on 15-year longitudinal respiratory function changes in adult patients with bronchial asthma[J].Int Arch Allergy Immunol,2013,162(4):323-329.
[5]	SUISSA S,ERNST P,BENAYOUN S,et al. Low-dose inhaled corticosteroids and the prevention of death from asthma[J].N Engl J Med,2000,343(5):332-336.
[6]	TOY E L,BEAULIEU N U,MCHALE J M,et al. Treatment of COPD:Relationships between daily dosing frequency,adherence,resource use,and costs[J].Respir Med,2011,105(3):435-441.
[7]	GAMBLE J,STEVENSON M,MCCLEAN E,et al. The prevalence of nonadherence in difficult asthma[J]. Am J Respir Crit Care Med,2009,180(9):817-822.
[8]	BERNSTEIN D I,BATEMAN E D,WOODCOCK A,et al. Fluticasone furoate (FF)/vilanterol (100/25mcg or 200/25mcg) or FF (100mcg) in persistent asthma[J]. J Asthma,2015,52(10):1073-1083.
[9]	DEVILLIER P,HUMBERT M,BOYE A,et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β₂-agonists (ICS/LABA) in patients with uncontrolled asthma:An open-label,randomized,controlled trial[J].Respir Med,2018,141:111-120.
[10]	JACQUES L,BAKERLY N D,NEW J P,et al. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study[J].J Asthma,2018:1-10.
[11]	张菲,江兵,缪李丽.糠酸氟替卡松治疗支气管哮喘疗效及安全性的系统评价[J].中国循证医学杂志,2017,17(1):33-39.
[12]	MOHER D,LIBERATI A,TETZLAFF J,et al. Preferred reporting items for systematic reviews and meta-analyses:The PRISMA statement[J].Int J Surg,2010,8(5):336-341.
[13]	BUSSE W W,O'BYRNE P M,BLEECKER E R,et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β₂-agonist vilanterol administered once daily for 52 weeks in patients ≥ 12 years old with asthma:a randomised trial[J].Thorax,2013,68(6):513-520.
[14]	WOODCOCK A,BLEECKER E R,LOTVALL J,et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma:a randomized trial[J].Chest,2013,144(4):1222-1229.
[15]	O'BYRNE P M,BLEECKER E R,BATEMAN E D,et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma[J].Eur Respir J,2014,43(3):773-782.
[16]	BATEMAN E D,O'BYRNE P M,BUSSE W W,et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone[J].Thorax,2014,69(4):312-319.
[17]	BLEECKER E R,LOTVALL J,O'BYRNE P M,et al. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma:a randomized trial[J].J Allergy Clin Immunol Pract,2014,2(5):553-561.
[18]	LIN J,KANG J,LEE S H,et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients:A randomized trial[J].Respir Med,2015,109(1):44-53.
[19]	BERNSTEIN D I,BATEMAN E D,WOODCOCK A,et al. Fluticasone furoate (FF)/vilanterol (100/25mcg or 200/25mcg) or FF (100mcg) in persistent asthma[J]. J Asthma,2015,52(10):1073-1083.
[20]	GROSS A S,GOLDFRAD C,HOZAWA S,et al. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase Ⅱb/Ⅲ trials[J]. Bmc Pulm Med,2015,15(1).
[21]	DEVILLIER P,HUMBERT M,BOYE A,et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β₂-agonists (ICS/LABA) in patients with uncontrolled asthma:An open-label,randomized,controlled trial[J].Respir Med,2018,141:111-120.
[22]	BIGGADIKE K. Fluticasone furoate/fluticasone propionate-different drugs with different properties[J].Clin Respir J,2011,5(3):183-184.
[23]	BIGGADIKE K,BLEDSOE R K,HASSELL A M,et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocoricoid receptor ligand binding domain[J].J Med Chem,2008,51(12):3349-3352.
[24]	SALTER M,BIGGADIKE K,MATTHEWS J L,et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease[J].Am J Physiol-Lung C,2007,293(3):L660-L667.
[25]	VALOTIS A,HOGGER P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate[J].Respir Res,2007,8:54.
[26]	ALLEN A,BAREILLE P J,ROUSELL V M. Fluticasone furoate,a novel inhaled corticosteroid,demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate[J].Clin Pharmacokinet,2013,52(1):37-42.
[27]	ROSSIOS C,TO Y,TO M,et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells[J].Eur J Pharmacol,2011,670(1):244-251.
[28]	PROCOPIOU P A,BARRETT V J,BEVAN N J,et al. Synthesis and structure activity relationships of long-acting β₂ adrenergic receptor agonists incorporating metabolic inactivation:an antedrug approach[J].J Med Chem,2010,53(11):4522-4530.

Message Board

Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis

doi: 10.3969/j.issn.1006-0111.2019.05.018

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views